These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. PPAR ligands: are they potential agents for cardiovascular disorders? Balakumar P, Rose M, Singh M. Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434 [Abstract] [Full Text] [Related]
3. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Gervois P, Fruchart JC, Staels B. Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841 [Abstract] [Full Text] [Related]
4. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications. Touyz RM, Schiffrin EL. Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410 [Abstract] [Full Text] [Related]
11. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials. Arck P, Toth B, Pestka A, Jeschke U. Biol Reprod; 2010 Aug 01; 83(2):168-76. PubMed ID: 20427759 [Abstract] [Full Text] [Related]
13. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance. Patsouris D, Müller M, Kersten S. Curr Opin Investig Drugs; 2004 Oct 01; 5(10):1045-50. PubMed ID: 15535425 [Abstract] [Full Text] [Related]
14. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Blaschke F, Takata Y, Caglayan E, Law RE, Hsueh WA. Arterioscler Thromb Vasc Biol; 2006 Jan 01; 26(1):28-40. PubMed ID: 16239592 [Abstract] [Full Text] [Related]
15. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Libby P, Plutzky J. Am J Cardiol; 2007 Feb 19; 99(4A):27B-40B. PubMed ID: 17307056 [Abstract] [Full Text] [Related]
16. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Circ Res; 2007 Oct 26; 101(9):948-56. PubMed ID: 17823371 [Abstract] [Full Text] [Related]
17. PPAR agonists and the metabolic syndrome. Staels B. Therapie; 2007 Oct 26; 62(4):319-26. PubMed ID: 17983557 [Abstract] [Full Text] [Related]
18. Selective activation of peroxisome proliferator-activated receptor (PPAR)alpha and PPAR gamma induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, Pecorini G, Stigliano E, Smith RC, Angelini F, Castellot JJ, Pola R. Diabetes; 2008 May 26; 57(5):1394-404. PubMed ID: 18268046 [Abstract] [Full Text] [Related]
19. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B, Staels B. Best Pract Res Clin Endocrinol Metab; 2007 Dec 26; 21(4):687-710. PubMed ID: 18054742 [Abstract] [Full Text] [Related]
20. Peroxisome proliferator-activated receptors and inflammation: take it to heart. Smeets PJ, Planavila A, van der Vusse GJ, van Bilsen M. Acta Physiol (Oxf); 2007 Nov 26; 191(3):171-88. PubMed ID: 17935522 [Abstract] [Full Text] [Related] Page: [Next] [New Search]